Valuation: Axogen, Inc.

Market Cap 2.34B 2.08B 1.95B 1.77B 3.34B 226B 3.38B 23.54B 9.11B 115B 8.79B 8.6B 369B P/E 2026 *
-91.5x
P/E 2027 * 515x
Enterprise Value 2.34B 2.08B 1.95B 1.77B 3.34B 226B 3.38B 23.54B 9.11B 115B 8.79B 8.6B 369B EV / Sales 2026 *
8.38x
EV / Sales 2027 * 6.89x
Free-Float
97.6%
Yield 2026 *
-
Yield 2027 * -
1 day-4.77%
1 week-7.85%
Current month-4.77%
1 month-19.97%
3 months-9.31%
6 months+18.88%
Current year+21.97%
1 week 39.68
Extreme 39.68
43.94
1 month 39.62
Extreme 39.62
49.06
Current year 27.54
Extreme 27.54
52.91
1 year 15.27
Extreme 15.2701
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Operating Officer 65 2025-01-09
Director TitleAgeSince
Director/Board Member 65 2016-08-31
Director/Board Member 58 2019-05-14
Chairman 70 2024-08-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Director

-3,500 0.0065%
8/11/26 Exercice

Director

40,059 0.0745%
8/10/26 Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
-4.77%-7.85%+123.39%+698.40% 2.34B
-3.34%-3.81%+22.95%+28.91% 241B
-4.42%-5.37%-0.53%-14.65% 149B
-1.33%+0.43%-8.40%+37.27% 142B
-0.96%-3.25%-54.90%-18.12% 62.65B
-1.31%-0.63%+11.64%+22.96% 49.1B
-3.27%-3.56%+20.28%+49.06% 46.99B
+0.73%+1.07%-18.77%-21.65% 47.13B
-1.23%+2.58%-3.86%+38.57% 45.65B
-3.15%-1.11%+33.06%+55.18% 41.81B
Average -2.31%-0.52%+12.49%+87.60% 82.76B
Weighted average by Cap. -2.53%+0.43%+3.58%+20.61%

Financials

2026 *2027 *
Net sales 280M 248M 232M 212M 398M 26.92B 404M 2.81B 1.09B 13.71B 1.05B 1.03B 44.03B 340M 302M 282M 257M 484M 32.73B 491M 3.42B 1.32B 16.67B 1.28B 1.25B 53.54B
Net income -24.19M -21.48M -20.09M -18.31M -34.47M -2.33B -34.94M -243M -94.09M -1.19B -90.82M -88.85M -3.81B 3.55M 3.15M 2.95M 2.68M 5.05M 342M 5.12M 35.64M 13.8M 174M 13.32M 13.03M 559M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-10-01 $39.92 -4.77% 1,600,587
26-09-30 $41.92 -1.23% 1,089,097
26-09-29 $42.44 -2.12% 1,407,685
26-09-28 $43.36 -0.07% 885,855
26-09-25 $43.39 +0.16% 1,221,856
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
39.92USD
Average target price
53.70USD
Spread / Average Target
+34.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock